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Abstract
BACKGROUND: Prader-Willi syndrome (PWS) is a rare genetic
neurodevelopmental disorder with different nutritional phases from suckling deficit
with failure to thrive to early onset of obesity. Hyperghrelinemia has been
described in PWS long before the development of obesity. Ghrelin is found in
both acylated (AG) and unacylated (UAG) forms in the circulation. In contrast to
AG, UAG has been shown to inhibit food intake and to be elevated in anorexia
nervosa. The present project is aiming to determine the underlying mechanisms
driving the different nutritional phases in PWS. METHODS: Measurement of at
least 4 h-fasting plasma acylated and unacylated ghrelin in 37 infants with a
genetic diagnosis of PWS aged from 1 month to 4 years and in 100 age-matched
controls without endocrine disorder recruited prior to minor surgery. One blood
sampling was analysed for each patient/control and clinical data were recorded.
Eleven PWS infants underwent repetitive blood samples at 3 or 6-month interv...
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Abstract
Background: Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder with different nutritional
phases from suckling deficit with failure to thrive to early onset of obesity. Hyperghrelinemia has been described in
PWS long before the development of obesity. Ghrelin is found in both acylated (AG) and unacylated (UAG) forms in
the circulation. In contrast to AG, UAG has been shown to inhibit food intake and to be elevated in anorexia
nervosa. The present project is aiming to determine the underlying mechanisms driving the different nutritional
phases in PWS.
Methods: Measurement of at least 4 h-fasting plasma acylated and unacylated ghrelin in 37 infants with a genetic
diagnosis of PWS aged from 1 month to 4 years and in 100 age-matched controls without endocrine disorder
recruited prior to minor surgery. One blood sampling was analysed for each patient/control and clinical data were
recorded. Eleven PWS infants underwent repetitive blood samples at 3 or 6-month intervals during routine visits.
Results: In infants with PWS, AG is not elevated (p = 0.45), UAG is significantly higher (p = 0.0044; confidence
interval 1.06;1.33) resulting in a low AG/UAG ratio (p = 0.0056; confidence interval 0.76;0.95) compared to controls.
Conclusion: Unlike children and adults with PWS that have high AG and AG/UAG ratio, infants with PWS have
elevated UAG that supports the concept of anorexia in the early phases of the disease. The change in AG/UAG ratio
possibly drives the switch from failure to thrive to obesity.
Clinical trial registration: NCT02529085.
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Background
Prader-Willi syndrome (PWS) is a rare genetic neurode-
velopmental disorder arising from the lack of expression
of paternally imprinted genes in the 15q11-q12 chromo-
somal region. This syndrome is characterized by various
nutritional phases, from suckling deficit with failure to
thrive in infancy to early onset of obesity with hyperpha-
gia [1]. The mechanisms driven those different phases
are not yet unravelled. In addition to enhance growth
hormone secretion, ghrelin has been shown to stimulate
appetite and increase adiposity. Ghrelin is found in both
acylated (AG) and unacylated (UAG) forms in the circu-
lation [2]. High AG levels have been described as poten-
tial cause of hyperphagia and obesity in PWS children
and adults [3, 4]. However, hyperghrelinemia has also
been described early in infancy in PWS long before the
development of obesity [5, 6]. In fact, UAG represents
approximately 90 % of the total ghrelin detected in
serum and has been shown to inhibit food intake [7, 8].
Interestingly, high UAG levels have been documented in
patients with restrictive anorexia nervosa [9–12]. The
present project is part of a European study aiming to
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determine the underlying mechanisms of different nutri-
tional phases in PWS.
We demonstrate normal circulating AG and increased
UAG levels in PWS infants compared to age-matched
controls thus driving a low AG/UAG ratio, independ-
ently from their BMI. This finding supports the concept
of anorexia in the early phases of the disease and may
drive the switch from failure to thrive to obesity.
Methods
The study population comprises 37 PWS and 100 control
infants with ages from 1 to 48 months. The PWS were
followed by two PWS reference centres, in Toulouse,
France, and Brussels, Belgium. PWS was genetically con-
firmed in all patients. The median age at genetic diagnosis
was 1 month [95 % confidence interval.0.5–2.5]. Twenty-
two (24 %) had a deletion of the 15q11-12 region, 51 % a
maternal unidisomy, 3 % a chromosomal translocation,
11 % an imprinting defect, and 11 % lacked a complete
genetic study and had abnormal methylation profiles.
Sixty-seven percent of the PWS infants started GH treat-
ment at a median age of 13 months [95 % confidence
interval 11.0;15.5]. Eleven PWS infants underwent repeti-
tive blood samples (twice in 9; three times in 2) at 3 or 6-
month intervals during routine visits. Control infants were
recruited prior to minor surgery and their medical records
were checked by the study team to exclude endocrine,
metabolic and neurological diseases.
The Flanders reference data [13] were used for height
and weight and the Niklasson reference data [14] for
birth weight, length and head circumference for the
Belgian infants, and the French reference data for
height and weight, birth weight, length and head cir-
cumference [15, 16] were used for the French infants.
BMI was calculated as kg/m2 and expressed as z-score,
adjusted for age and sex. Cole BMI reference data were
used for both Belgian and French patients [17].
The nutritional phases are reported as described by
Miller et al. [1] and were used to score the eating behaviour
of the PWS infants: phase 1a “Hypotonia with difficulty
feeding”, phase 1b “No difficulty feeding and growing ap-
propriately on growth curve”, phase 2a “Weight increasing
without an increase in appetite or excessive calories”, phase
2b “Weight increasing with an increase in appetite”, phase
3 “Hyperphagia, rarely feels full”, phase 4 “Appetite no
longer insatiable”.
Blood samples were collected in the morning after a
minimum 4-h fast in all infants. Collection is a critical
step to have reliable measurements of ghrelin. To prevent
degradation of the plasma ghrelin levels, blood samples
were collected in EDTA tubes maintained at +4 °C con-
taining the anti-protease 4-(2-aminoethyl) benzenesulfonyl
fluoride hydrochloride (AEBSF, Sigma-Aldrich Chemicals)
at a concentration of 2 mg/ml. Blood was centrifuged at
4 °C, and plasma was quickly frozen on dry ice. Samples
were stored at−80 °C and assayed within 3–6 months fol-
lowing collection.
Plasma AG and UAG levels were assessed in duplicate
(10–50 μL per well) in one laboratory using two-step
double antibody sandwich EIAs, obtained from SPIBio
(Bertin Pharma, France; A05306 and A05319, respectively).
Assays were performed according to the manufacturer’s
instructions. In summary, standards, quality controls
and samples were incubated in the plate for 2 h at room
temperature without tracer. After a 3× wash, tracer
antibody was added and incubated for 2 h at room
temperature. Following a 5× wash, Ellman’s reagent
was added and incubated for approximately 45 min
until satisfactory colour development. Last, absorbance
was measured at 405 nm using a VictorX4 plate reader
(PerkinElmer, Groningen, Netherlands). Data were ana-
lysed using Graphpad Prism 5 (La Jolla, California). A
sigmoidal third-order (cubic) polynomial fitting was
used to determine concentrations from the calibration
curves. This resulted in r2 values >0.99 in the majority
of the assays. Intra-assay coefficients of variation (CVs)
for AG and UAG were 8.2 and 11.4 % and inter-assay
CVs for AG and UAG were 3.9 and 11.0 %. CVs were
determined over ten and nine assays for AG and UAG,
respectively. Samples had inter-duplicate CVs of <20 %
for both AG and UAG. The AG/UAG ratio was com-
puted as AG divided by UAG.
Plasma concentrations of insulin were determined using
xMAP technology (Luminex, Austin, TX, USA) with 6-
plex kits from Millipore (Ref HMHMAG-34 K, Millipore,
Billerica, MA, USA). Assays were performed in duplicate
for all standards, samples and internal controls in two sep-
arate plates that were loaded the same day. Recovery and
intra- and inter- assay CVs were calculated to validate the
assay. In France, serum IGF-I levels were measured using
the IDS-iSYS automated chemiluminescence assay (Im-
munodiagnostic Systems, UK). In Belgium, IGF-I levels
were measured using a two-step double antibody im-
munoassay (Liaison XL, DiaSorin).
Data are expressed as median [95 % confidence interval]
or percent. AG and UAG levels and AG/UAG ratios were
log-transformed (natural logarithm) to obtain a normal
distribution. Comparative analyses were conducted using
Mann–Whitney or Chi-square tests and correlation ana-
lysis using linear generalized estimating equations with a
common correlation between samples from the same pa-
tients, with p-value calculation according to Pan et al. and
Chaganty et al. [18, 19]. For Additional file 1: Fig. S1,
we used nonlinear regressions by B-splines to draw the
curves. Because the curves are compatible with linear
regressions, we did not use nonlinear regressions for
the statistical analysis. A p-value <0.05 was considered
as significant.
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Results
PWS infants not surprisingly differed from controls in
gestational age, delivery mode, birth weight, and breast
feeding (Table 1).
These infants were representative of the classical PWS
population regarding birth, auxological and anthropo-
metric data (19). PWS infants started growth hormone
(GH) treatment at a median age 13.0 months [confi-
dence interval 11.0;15.5]. The age at different nutritional
phases is consistent with the description of Miller et al.
[1], as shown in Table 1. PWS infants showed normal
Body Mass Index (BMI) until 2 years of age, except for
six of them, with four being underweight and two obese,
as shown in Fig. 1a and b.
Circulating AG levels were not significantly different
between the two groups (p = 0.45), whereas higher UAG
levels were observed in PWS infants (p = 0.0044; ratio =
1.19 [confidence interval: 1.06;1.33] Fig. 2 and Additional
file 1: Fig. S1). Consequently, the AG/UAG ratio was
significantly lower in PWS infants compared with con-
trols p = 0.0056; ratio = 0.85 [confidence interval: 0.76;0.95]
Fig. 2 and Additional file 1: Fig. S1). AG levels remained
stable between 3 and 48 months in both groups, whereas
UAG levels decreased with age (p = 0.0031); we do not
Table 1 Description of the population
PWS (n = 37) Controls (n = 100) P valuea
At birth
Gestational age (weeks) 37.5 (36.0;39.0) 39.5 (39.0;39.5) 0.008
Caesarean delivery (%) 67 % 28 % <0.0001
Birth length-z-score −0.85 (−1.08;–0.60) −0.29 (−0.56;–0.06) 0.010
Birth weight-z-score −1.65 (−1.90;–1.31) −0.26 (−0.50;–0.02) <0.0001
Breast feeding (%) 11 %b 66 % <0.0001
Duration of breast feeding (days) 92 (45;151) 135 (99;167) NS
At inclusion
Age (years) 1.8 (1.4;2.3) 2.0 (1.7;2.2) NS
Sex ratio (% male) 57 % 49 % NS
Height-z-score −0.84 (−1.23;–0.48) 0.53 (0.25;0.80) <0.0001
Weight-z-score −1.06 (−1.49;–0.64) 0.06 (−0.20;0.35) <0.0001
BMI-z-score −0.86 (−1.31;–0.32) −0.40 (−0.70;–0.10) NS
GH treatment (%) 68 % NA NA
Age at start of GH treatment (months) 13.0 (11.0;15.5) NA NA
GH dose (mcg/kg/d) 0.029 (0.027;0.031) NA NA
IGF-I (ng/ml) 98 (61;135) NA NA
Insulin (pg/ml) 167 (141;194) 178 (160;196) NS
PWS features
Age at genetic diagnosis (months) 1.0 (0.5;2.5)
Type of genetic diagnosis (%)
Deletion 24 %
Maternal disomy 51 %
Translocation 3 %
Imprinting defect 11 %
Abnormal methylation profile 11 %
Nutritional phase at inclusion
1a [%−age (months(range))] 43 %−4 (2;23)
1b [%−age (months(range))] 20 %−29 (11;45)
2a [%−age (months(range))] 23 %−38 (21;46)
2b [%−age (months(range))] 14 %−34 (26;37)
Table 1 gives % or Hodges-Lehmann’s medians and their 95 % confidence interval
Abbreviations: NA Not applicable, NS Not Significant
aDifferences between PWS vs. controls were tested with Mann–Whitney or Chi-square tests
bMother’s milk was given without complete breast feeding to PWS infants
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detect a difference of the slope between PWS infants and
controls (p = 0.51). Interestingly UAG levels tend to de-
crease from phase 1a to phase 2b (respectively: median
(min-max) 205 pg/ml (37–941) in phase 1a (n = 15),
163 pg/ml (36–486) in phase1b (n = 13), 175 pg/ml (69–
255) in phase 2a (n = 8) and 107 pg/ml (39–314) in phase
2b (n = 9)) but this is not statistically significant. AG levels
were negatively correlated with BMI z-score (p = 0.017)
and insulin levels (p = 0.047), even after adjustment for age
and group. UAG levels were negatively correlated with in-
sulin levels (p = 0.027), even after adjustment for age and
group. No correlation was observed between UAG levels
and BMI z-score (p = 0.13). AG and UAG levels did not
significantly differ between the GH-treated and untreated
PWS patients (respectively, p = 0.57; p = 0.74) (Fig. 3).
However, UAG levels are positively correlated with age in
the very young infants not yet receiving GH treatment
(N = 11) (p = 0.0088) (Fig. 3). In addition, nasogastric
tube feeding did not significantly influence AG and
UAG levels (data not shown).
Discussion
Our results demonstrate for the first time that circulat-
ing UAG is elevated in PWS infants and decreases with
age, whereas AG is normal and remains stable from 1 to
48 months. Hence, we confirm our previous finding that
total hyperghrelinaemia manifests early in life in PWS
[5] and we show here that it is due to elevated UAG.
High UAG levels with normal AG levels result in a low
AG/UAG ratio, particularly in the youngest infants,
which may drive the spontaneous poor feeding observed
during the first months of life in PWS. Poor feeding that
may lead to failure to thrive in the early phases of PWS
is classically explained by the presence of severe hypo-
tonia and suckling deficit [20, 21]. Our results suggest
that anorexia also plays a role in this poor feeding and
may be driven by increased UAG and therefore a relative
deficit in AG for their UAG levels. Indeed, UAG has
been shown in mice and humans to decrease food intake
[7, 8]. Moreover, high circulating UAG and low AG/
UAG ratio have consistently been reported in adults
with restrictive anorexia nervosa [9–12] in contrast with
those with constitutional thinness and normal feeding
behaviour who display normal UAG levels [22]. These
data suggest that high UAG is more related with feeding
behaviour than BMI. Indeed we show in this study that
PWS infants have high circulating UAG with low AG/
UAG ratio and poor appetite but normal BMI due to
adequate calorie intake (data not shown) through naso-
gastric tube feeding if necessary. We propose that the
low AG/UAG ratio reflects anorexia in the postnatal
period of PWS. In patients with anorexia nervosa circu-
lating UAG levels normalized after a long-term weight
regain. In contrast UAG levels remained elevated in
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Fig. 1 Plotted BMI of the PWS girls a and boys b. Open circles: PWS infants not treated with GH; dark circles: PWS infants treated with GH. When
several measures had been taken for one individual, the circles are linked
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our well-nourished PWS infants suggesting a peculiar
dysfunction in this disease and/or at this period of life.
The relative excess of UAG may be due to a defect or
abnormal regulation of the unique enzyme that acylates
UAG in its serine 3 in mammals, the so-called Ghrelin
O-AcylTransferase (GOAT) [23] or, conversely, to in-
creased deacylation of AG by circulating nonspecific
deacylases [24]. Although GOAT is a membrane-bound
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Fig. 2 Acylated (AG) a, unacylated (UAG) b ghrelin levels and AG/UAG ratio c according to age in both groups: red: PWS; blue: control children.
Comparative analyses were conducted using linear generalized estimating equations with a common correlation between samples from the
same patients, with p-value calculation according to Pan et al. and Chaganty et al. [18, 19]. PWS vs. Controls: p = 0.45 (A), p = 0.0044 (B), p = 0.0056
(C), see Additional file 1: Fig. S1
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enzyme, it has been shown to circulate in plasma but
radioimmunoassay is not yet available, to our knowledge
[25]. GOAT is present in human plasma and GOAT pro-
tein levels depend on the metabolic environment, with
decreased levels in anorexic patients and increased levels
in morbidly obese patients [25]. GOAT, as the unique
known enzyme acylating ghrelin, may counteract the
adaptive changes in ghrelin observed under these condi-
tions and ultimately contribute to the development or
maintenance of anorexia and obesity. Studies in rodents
and humans suggest that ghrelin acylation can be modi-
fied by nutritional status and that the availability of
medium-chain fatty acids (MCFAs) is the rate-limiting
step for the acylation [26]. Greater insight into the
pathophysiological mechanisms is needed. Nevertheless,
we have no evidence of an abnormal nutritional status of
our PWS infants. Indeed all our PWS infants had ad-
equate calorie intake. Moreover, whatever the BMI (low,
normal or increased), it is well known that infants with
PWS display an excess of fat mass [27, 28]. Fat mass was
measured by DXA scanning in 15 of our PWS patients,
AG levels were correlated to fat mass (p = 0.000089) but
no correlation between fat mas and UAG levels was
found (p = 0.13, data not shown). Even in the presence
of higher fat mass, PWS children are hypoinsulinemic
in comparison to age-, gender-matched obese controls
[29, 30]. Agreeing with several studies in normal weight
and obese children [31] and in PWS children and
adults [32, 33], we also showed an inverse relationship
between insulin levels and AG and UAG ghrelin levels.
As UAG levels are negatively correlated to insulin
levels, lower insulin levels could explain high UAG
levels. It is however unlikely as we found, at this age,
similar insulin levels between controls and PWS infants.
GH also did not affect UAG levels. The effect of GH treat-
ment on ghrelin levels has never been described in such
young PWS patients. Recently, a study in PWS adults has
showed that GH treatment did not affect UAG levels [34].
We recently reported AG and UAG levels in older
PWS children and adults in comparison with lean and
obese controls [35]. Interestingly, the AG/UAG ratio at
this age is increased in PWS due to increased AG and
normal UAG levels, which is the opposite situation ob-
served in PWS infants. This suggests an intrinsic defect
in AG/UAG in PWS, resulting in a relative AG deficit
early in life and a subsequent excess in later life that
correlates with the switch in feeding behaviour. The
mechanisms remain to be elucidated.
Due to the known effects of AG on brain plasticity,
memory and cognition [36] these relatively low AG levels
in infants may contribute to PWS patients’ intellectual dis-
ability later in life. The early diagnosis of PWS, currently
at 1 to 2 months, thus provides a window of opportunity
for implementing treatment that may modulate the
AG/UAG ratio and thereby may improve both the feed-
ing difficulties and cognition.
Conclusion
We confirmed that total hyperghrelinaemia is observed
at all ages throughout life in PWS, with a different AG/
UAG ratio driving opposite phenotypes: anorexia in in-
fants and hyperphagia with deficit of satiety in later life.
The mechanism for the switch in this ratio now has to
be deciphered. Nevertheless, based on this finding, new
therapeutic approaches should focus on the balance of
AG/UAG ratio, with drugs to supply either AG or UAG
depending on age.
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Additional file 1: Figure S1. Nonlinear regression (± SEM) of acylated
(AG) (A), unacylated (UAG) ghrelin (B) levels and AG/UAG ratio (C)
according to age in both groups. Black line: control; Red line: PWS
infants. For Supplementary Figure1, we used nonlinear regressions by
B-splines to draw the curves. Because the curves are compatible with
linear regressions, we did not use nonlinear regressions for the statistical
analysis. (DOCX 86 kb)
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